With so many biotech stocks making big moves and pharmaceutical merger activity moving faster than anything else right now, we turned to one of the smartest analysts in the lucrative biotech field to give us his take on what we should be doing…

Reading between the lines is key to successful stock market investing today, says Andrew Snyder. Pfizer’s (NYSE:PFE) announcement that it is looking to acquire rival companies in 2009 signals that organic growth will be hard to come by. And that’s bad news for shareholders. Andrew says savvy investors can bet against the company by short selling or buying put options.

New breakthroughs in adult stem cell technology offer staggering implications for medical science, says Patrick Cox. And a massive opportunity for investors. As Big Pharma move in, Patrick says biotech companies involved in stem cell research and RNA technology could become the “investment of a lifetime.”

Martin Hutchinson analyses what a Democrat landslide means for investors. He says nuclear and clean energy stocks, auto manufacturers, generic drug producers and muni bonds are a “buy”. But fossil fuel companies and financial institutions should be avoided.

In 2007, the Maryland lottery had a record year. It pulled in more than $1.5 billion of revenue… $50 million went toward running lottery operations, $110 million to retailers, $500 million to the state, and winners collected the remaining $900 million.

One of the drug industry’s biggest superstars right now is a cancer drug called Sutent.

Back in December, my friend Steve Sjuggerud described a British spending spree taking place in America. At the time, the pound was worth about $1.95, and Brits were enjoying a 50% discount on their Christmas shopping across the pond.

The Japanese have gone on a shopping spree. In the last six months, two of Japan’s biggest drugmakers in have scooped up two midsized U.S. biotech firms at nothing short of whopping valuations. This international binge bodes well for us biotech investors.

Back in December, I told you the bleak story of Neurocrine Biosciences (NBIX). A week earlier, the company had received a crushing blow from the FDA, dished out in a notorious “approvable letter.” Approvable letters are the FDA’s way of turning a “yes/no” decision on a new drug into a “maybe.”

Cash McDash is on a roll.  Just don’t give him grief over his new nickname.  There is an art to making money in bear market rallies. Cash explains. Is this China-based pharma company a great buy… a great short… or none of the above?